Our biggest discoveries of the year If you have trouble viewing this email, view it online. connect with us   DECEMBER 2021   10 Ways Cancer Treatment Progressed in 2021 In cancers of the lung, breast, prostate, and more, MSK researchers advanced patient care. Get the details       Why Are Black Women at Highest Risk for Lymphedema? Race and ethnicity may play a role in who is most likely to get this common side effect after surgery. Theresa (above right) is participating in a clinical trial exploring why. See the findings   The Latest in Breast Cancer Treatment At the San Antonio Breast Cancer Symposium, Neil Iyengar (above) shared how customized diet and exercise plans may help prevent and treat the disease. Read more     Personalize Your Updates Get only the MSK news you want. If you tell us what you’re interested in, we will send you the updates you want to read.   Go to my preferences   Tune In: The Future of Cancer Drugs Twenty years ago, Dr. Charles Sawyers was pivotal to developing a game-changing cancer drug called Gleevec. In this podcast episode, Dr. Diane Reidy-Lagunes talks with him about what’s next in cancer medicine. Is another silver bullet on the horizon? Listen here   The 2021 Scientific Discoveries Laying the Foundation for Future Cancer Therapies New insights into diabetes, sugar, and the immune system are among those blazing a trail forward in cancer research. Read more   Contact Us We welcome your feedback and encourage you to send us a message at: [email protected] Helpful Resources To Make an Appointment: 800-525-2225 To Reach Us by Phone: 212-639-2000 Find an MSK location   ©2021 Memorial Sloan Kettering Cancer Center 1275 York Ave., New York, NY 10065 US December 2021   To ensure you continue to receive emails from MSK Now, add us to your address book or safe list. To unsubscribe, click here. This message was sent to [email protected]. To manage your preferences, click here. You are receiving this email because you subscribed to e-newsletters from MSK Now. To forward this email click here.